Leerink Partners initiated coverage on Voyager Therapeutics with a new price target

10/16/24 7:42:40 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Leerink Partners initiated coverage of Voyager Therapeutics with a rating of Outperform and set a new price target of $15.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VYGR

Date	Price Target	Rating	Analyst
1/10/2025		Overweight	Cantor Fitzgerald
12/2/2024	$12.00	Buy	Citigroup
11/29/2024	$7.00 → $11.00	Outperform	Wedbush
10/16/2024	$15.00	Outperform	Leerink Partners
3/26/2024	$22.00	Buy	Guggenheim
3/19/2024	$30.00	Buy	H.C. Wainwright
3/7/2024	$16.00	Buy	Citigroup
1/2/2024	$14.00	Equal Weight → Overweight	Wells Fargo